Literature DB >> 10946891

A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition.

H G Burger1, E C Dudley, J Cui, L Dennerstein, J L Hopper.   

Abstract

The aims of this study were to describe, in relation to date of final menses, the average androgen levels of women in the years before and after this date, and to determine the extent to which these average levels were dependent on age and body mass index (BMI) and the degree of tracking in residual androgen levels, or the extent to which individuals above (below) the mean for their age or time relative to final menstrual period (FMP) and BMI remain above (below) the mean as time progresses. Serial levels of serum sex hormone-binding globulin (SHBG), testosterone (T), and dehydroepiandrosterone sulfate (DHEAS) were measured annually in 172 women from the Melbourne Women's Midlife Health Project who experienced a natural menopause during 7 yr of follow-up. Fasting blood samples were drawn between days 4-8 if women were still menstruating or after 3 months of amenorrhea. The free androgen index (FAI) was calculated as the ratio ofT to SHBG x 100. Means of the log-transformed androgen levels were analyzed as a double logistic function of time relative to FMP as well as age and BMI, and correlations between repeated androgen levels were measured. Mean SHBG levels decreased by 43% from 4 yr before to 2 yr after the FMP. The time of most change was 2 yr before FMP [95% confidence interval (CI), 0.8-3.2]. SHBG levels were, on the average, 5% lower for each halving of estradiol (E2) levels and 4% lower for each kilogram per m2 of BMI (P < 0.0001). About one third of the decline in SHBG was explained by E2 and BMI. After adjusting for all variables, SHBG showed strong tracking. Mean T levels did not vary with time relative to FMP and were independent of age and BMI. Residual values of T showed weak tracking. The FAI increased by 80% from 4 yr before FMP to 2 yr after FMP, and changed maximally 2.2 yr before FMP (95% CI, 1.2-3.2). The FAI was not related to age or E2, but was, on the average, 4% higher for each kilogram per m2 of BMI (P < 0.0001). Residual values of FAI showed moderate tracking. Mean DHEAS levels were not related to the FMP, but were 1.5% lower for each year of age (P < 0.01) and 3.8% lower for each kilogram per m2 of BMI (P < 0.0001). Residual values of DHEAS showed strong tracking. It is concluded that SHBG and FAI levels change at the time of the menopause, at least partially due to the decline in E2. DHEAS decreases as a function of age, not time relative to FMP, and T remains unchanged during the menopausal years. SHBG and DHEAS show a high degree of stability within an individual over time.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946891     DOI: 10.1210/jcem.85.8.6740

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  72 in total

1.  Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN).

Authors:  Joyce T Bromberger; Laura L Schott; Howard M Kravitz; Maryfran Sowers; Nancy E Avis; Ellen B Gold; John F Randolph; Karen A Matthews
Journal:  Arch Gen Psychiatry       Date:  2010-06

Review 2.  Menopause and Sexuality.

Authors:  Kimberley Thornton; Judi Chervenak; Genevieve Neal-Perry
Journal:  Endocrinol Metab Clin North Am       Date:  2015-09       Impact factor: 4.741

Review 3.  Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women.

Authors:  John H Morrison; Roberta D Brinton; Peter J Schmidt; Andrea C Gore
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

Review 4.  Pharmacological therapy for female sexual dysfunction: has progress been made?

Authors:  Susan R Davis; Esme A Nijland
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Sexual function in women: what is normal?

Authors:  Claudine Domoney
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-05

Review 6.  Estrogen: a master regulator of bioenergetic systems in the brain and body.

Authors:  Jamaica R Rettberg; Jia Yao; Roberta Diaz Brinton
Journal:  Front Neuroendocrinol       Date:  2013-08-29       Impact factor: 8.606

Review 7.  Management of the Perimenopause.

Authors:  Lara Delamater; Nanette Santoro
Journal:  Clin Obstet Gynecol       Date:  2018-09       Impact factor: 2.190

8.  Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation.

Authors:  Imke Janssen; Lynda H Powell; Sybil Crawford; Bill Lasley; Kim Sutton-Tyrrell
Journal:  Arch Intern Med       Date:  2008-07-28

9.  Transthyretin is up-regulated by sex hormones in mice liver.

Authors:  I Gonçalves; C H Alves; T Quintela; G Baltazar; S Socorro; M J Saraiva; R Abreu; C R A Santos
Journal:  Mol Cell Biochem       Date:  2008-06-22       Impact factor: 3.396

Review 10.  Dehydroepiandrosterone and dehydroepiandrosterone sulphate in atopic allergy and chronic urticaria.

Authors:  Alicja Kasperska-Zajac; Zenon Brzoza; Barbara Rogala
Journal:  Inflammation       Date:  2008-02-21       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.